Whether you’re chasing fall colors or fewer crowds, these national parks offer some of the best autumn travel experiences in the country.
AI’s big debt load. Moving backward on defense tech. Why we need to talk about CPUs. All that and more in this week’s Prototype.
The Chinese-owned social network has been flooded with advertisements pushing street drugs and prescription pills like codeine, benzos and Adderall.
For four generations, Rome’s Angelini family has built a $2.5 billion operation with drugs for depression and epilepsy in Europe. Now it’s bought its way into the U.S. market.
In this week’s edition of InnovationRx, we look at Summa Health’s first tech bets, the healthcare leaders on Forbes Veteran 250 list, BioMarin’s acquisition of an early-stage bone disease therapy, and more.
Despite racking up more than $2 billion in losses while sticking to a do-it-yourself strategy, buy-now, pay-later pioneer Affirm is finally profitable—and worth $25 billion.
Chairman and CEO Wang Xingxing’s fortune surged nearly sevenfold to $16 billion as investors bet on China’s leading humanoid robot maker.
Despite billions in revenues, most influencers and their popular channels carry too much “key-person” risk for institutional investors. This UK firm has figured out how to turn viral videos into evergreen products.
From wildlife encounters to trail etiquette, discover how to avoid becoming a “touron” during your next national park adventure.
This week’s Current Climate newsletter also looks at big funds flowing into long-duration battery makers and the impact of a big proposed cut to NOAA’s budget.